Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP

Abstract

Background: T cell/histiocyte-rich large B cell lymphoma (THRLBCL) is a rare morphological variant of diffuse large B cell lymphoma (DLBCL), accounting for 1-3% of all DLBCLs. However, its impact on treatment outcome and prognosis is still not clearly defined. Methods: We compared the clinical outcomes between THRLBCL and DLBCL, not otherwise specified (NOS), in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results: Data from 11 patients with THRLBCL were matched to 33 patients with DLBCL-NOS. Patients were matched by five established prognostic factors of the International Prognostic Index, including age, Ann Arbor stage, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level and the number of extranodal involvement. There was no significant difference in the complete response rate to R-CHOP between THRLBCL (91%, 10/11) and DLBCL-NOS (97%, 32/33; p = 0.442). The 3-year event-free survival rate was 81% for both THRLBCL and DLBCL-NOS (p = 0.813). The 3-year overall survival rates were 75 and 81%, respectively (p = 0.719). Conclusions: The treatment outcomes of THRLBCL are similar to those of DLBCL-NOS. The addition of rituximab to CHOP seems to be helpful for the management of THRLBCL, as it is for DLBCL-NOS.

Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature

“…Recently, CHOP chemotherapy in combination with rituximab (R-CHOP) is used in T/HRBCL as it is used in all CD20 positive nodal and extranodal lymphomas[11,32]. Kim et al[33] reported that there was no significant difference in the CR rate to R-CHOP between T/HRBCL (91%) and DLBCL (97%). The 3-year OS rates were 75% for T/HRBCL and 81% for DLBCL, respectively ( P = 0.719).…”

T-cell/histiocyte rich large B-cell lymphoma

“…The treatment outcomes of THRLBCL are similar to those of DLBCL. The addition of rituximab to CHOP seems to be helpful for the management of THRLBCL, as it is for DLBCL (Kim et al, 2014).…”

Matched-Pair Analysis of Open versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Cell Carcinoma

“…The approach was recently used to compare short-term outcomes in 22 pairs undergoing robotic nephroureterectomy or LNU for UUT-UCC [14]. It has also been used to compare lithotripsy and ureteroscopy for upper tract ureteric calculi [15] and to compare outcomes after chemotherapy in small numbers of patients with lymphoma [16], squamous cell carcinoma [17,18], primary glioblastoma [19] and macular degeneration [20]. It is therefore a valid approach with which to compare outcomes in rare conditions.…”